Wolinsky JSMultiple
sclerosis. In Current Neurology, 1993 Vol 13, ed.
Appel
SH.Chicago:
Mosby-Year Book, Inc., pp
167-207.
2.
Jacobs LD, Beck RW,
Simon
JH, et al. Intramuscular interferon beta-1a
therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study
Group. N Engl J Med2000;
343: 898-904.
3.
Comi G., Filippi M.,
Barkhof
F., et al. Effect of early interferon
treatment on conversion to definite multiple sclerosis: A randomised
study. Lancet2001; 357:
1576-1582.
4.
Lublin FD, Reingold
SCDefining the clinical course of multiple
sclerosis: Results of an international survey.
Neurology1996; 46:
907-911.
5.
Whitaker JN, Kachelhofer RD,
Bradley
EL, et al. Urinary myelin basic protein-like
material as a correlate of the progression of multiple sclerosis.
Ann Neurol1995; 38:
625-632.
6.
Beck RW, Cleary PA,
Trobe
JD, et al. The effect of corticosteroids for
acute optic neuritis on the subsequent development of multiple sclerosis. The Optic
Neuritis Study Group . New Engl J Med1993;
329: 1764-1769.
7.
Filippi M., Horsfield MA,
Morrissey
SP, et al. Quantitative brain MRI lesion
load predicts the course of clinically isolated syndromes suggestive of multiple
sclerosis. Neurology1994;
44: 635-641.
8.
Noseworthy JH , Wolinsky JS,
Lublin
FD, et al. Linomide in relapsing and
secondary progressive MS: Trial design and clinical results .
Neurology2000; 54:
1726-1733.
9.
Wolinsky JS, Narayana PA,
Noseworthy
JH, et al. Linomide in relapsing and
secondary progressive MS: MRI results .
Neurology2000; 54:
1734-1741.
10.
European Study Group on interferon
beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of
interferon beta-1b in treatment of secondary progressive multiple
sclerosis. Lancet1998;
352: 1491-1497.
11.
Secondary Progressive Efficacy Clinical Trial of Recombinant
Interferon-beta-1a in MS (SPECTRIMS) Study
Group.Randomized controlled trial of
interferon-beta-1a in secondary progressive MS: Clinical results.
Neurology2001; 56:
1496-1504.
12.
Kappos L., Moeri D.,
Radue
EW, et al. Predictive value of
gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in
disability or impairment in multiple sclerosis: A meta-analysis.
Lancet1999; 353:
964-969.
13.
Van Walderveen Maa, Lycklama a Nijeholt
GJ, Ader HJ, et al. Hypointense
lesions on T1-weighted spin-echo magnetic resonance imaging—Relation to clinical
characteristics in subgroups of patients with multiple sclerosis .
Arch Neurol2001; 58:
76-81.
14.
van Walderveen MA, Kamphorst W.,
Scheltens
P., et al. Histopathologic correlate of
hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.
Neurology1998; 50:
1282-1288.
15.
van Waesberghe JH, van Walderveen MA,
Castelijns
JA, et al. Patterns of lesion development in
multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and
magnetization transfer MR. AJNR1998;
19: 675-683.
16.
Filippi M., Rovaris M.,
Rocca
MA, Sormani MP, Wolinsky JS,
Comi
G., et al. Glatiramer acetate reduces the
proportion of new MS lesions evolving into 'black holes'.
Neurology2001 ; (in press).
17.
Filippi M., Wolinsky JS,
Sormani
MP, Comi G., et al. Enhancement
frequency decreases with increasing age in relapsing-remitting multiple
sclerosis. Neurology2001;
56: 422-423.
18.
Goodkin DE, Rooney WD,
Sloan
R., et al. A serial study of new MS lesions
and the white matter from which they arise.
Neurology1998; 51:
1689-1697.
19.
Silver NC, Tofts PS,
Symms
MR, Barker GJ, Thompson AJ,
Miller
DHQuantitative contrast-enhanced magnetic
resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: A
preliminary study. Multiple Sclerosis2001;
7: 75-82.
20.
McGowan JC, Filippi M.,
Campi
A., Grossman RIMagnetisation
transfer imaging: Theory and application to multiple sclerosis .
J Neurol Neurosurg Psych1998; 64(Suppl
1): S66-S69.
21.
Richert ND, Ostuni JL,
Bash
CN, Leist TP, McFarland HF,
Frank
JAInterferon beta-1b and intravenous
methylprednisolone promote lesion recovery in multiple sclerosis.
Multiple Sclerosis2001; 7:
49-58.
22.
Filippi M., Iannucci G.,
Tortorella
C., et al. Comparison of MS clinical
phenotypes using conventional and magnetization transfer MRI.
Neurology1999 ; 52:
588-594.
23.
Rocca MA, Mastronardo G.,
Rodegher
M., Comi G., Filippi
M.Long-term changes of magnetization
transfer-derived measures from patients with relapsing-remitting and secondary
progressive multiple sclerosis . AJNR1999;
20: 821-827.
